Efficacy and safety of anti-angiogenesis medicines for advanced soft tissue sarcoma: a meta-analysis | Zendy

Yuxuan Wang | Zendy; Xiaobo Dai | Zendy; Yuxi Zhu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and safety of anti-angiogenesis medicines for advanced soft tissue sarcoma: a meta-analysis

Author(s) -

Yuxuan Wang,

Xiaobo Dai,

Yuxi Zhu

Publication year - 2020

Publication title -

translational cancer research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.254

H-Index - 30

eISSN - 2219-6803

pISSN - 2218-676X

DOI - 10.21037/tcr.2020.01.47

Subject(s) - medicine , hazard ratio , meta analysis , adverse effect , oncology , cochrane library , angiogenesis , soft tissue sarcoma , relative risk , confidence interval , gastroenterology , surgery , soft tissue

Soft tissue sarcomas (STSs), a series of mesenchymal original malignant diseases, account for approximately 1% of human tumors (1). According to the World Health Organization (WHO), STSs include more than 70 subtypes (2), and the common subtypes of them are pleomorphic undifferentiated sarcoma, liposarcoma, leiomyosarcoma, synovial sarcoma, angiosarcoma. Surgery-based treatment might be performed to treat early-stage of STS, but the prognosis of STS remains poor, regardless of surgery, radiotherapy, and chemotherapy. On the other hand, Chemotherapy is one of the standard treatments for the advanced stage of STS. Doxorubicin (ADM) alone or in combination with ifosfamide (ADM + I-FO) is the first-line chemotherapy regimen for advanced STS. Other medicines, such as dacarbazine, Original Article

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research